Romano Kathryn's Form 4 filing
Krystal Biotech, Inc. (KRYS) · filed Feb 28, 2025
- Accession no.
- 0001801385-25-000002
- Filed
- Feb 28, 2025
- Trade date
- Feb 26-28, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $131.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Romano KathrynCIK 0001801385 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2025 | Common Stock | FTax withholdingDisposed | −2,268 | $176.39F2 | −$400,052.52 | 13,354 | Direct | |
| Feb 27, 2025 | Common Stock | SSaleDisposed | −750 | $175.22F4 | −$131,415 | 12,604 | Direct | |
| Feb 28, 2025 | Common Stock | MOption exerciseAcquired | +5,000 | $0.00 | $0 | 17,604 | Direct | |
| Feb 28, 2025 | Common Stock | FTax withholdingDisposed | −2,315 | $179.25F7 | −$414,963.75 | 15,289 | Direct | |
| Feb 28, 2025 | Common Stock | MOption exerciseAcquired | +7,500 | $0.00 | $0 | 22,789 | Direct | |
| Feb 28, 2025 | Common Stock | FTax withholdingDisposed | −3,471 | $179.25F7 | −$622,176.75 | 19,318 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 0 | Direct | |
| Feb 28, 2025 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 7,500 | Direct | |
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +10,000 | $0.00 | $0 | 10,000 | Direct | |
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +2,200 | $0.00 | $0 | 2,200 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The closing price on February 26, 2025 of the Company's common stock on the Nasdaq Global Select Market.
Referenced by the price of 1 transaction in Table I.
- F4
The transaction was executed in multiple lots at the same price, $175.22.
Referenced by the price of 1 transaction in Table I.
- F7
The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market.
Referenced by the price of 2 transactions in Table I.